Lyell Immunopharma, Inc. (LYEL) vs Nautilus Biotechnolgy, Inc. (NAUT)
A side-by-side comparison of Lyell Immunopharma, Inc. and Nautilus Biotechnolgy, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LYEL
Lyell Immunopharma, Inc.
$8.74HealthcareDelayed quote: Oct 6, 2026, 11:49 AM EDT
NAUT
Nautilus Biotechnolgy, Inc.
$1.97HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Total return — LYEL vs NAUT
growth of $100 · dividends reinvested · last 5yLYEL -97.3% (-51.5%/yr)NAUT -80.8% (-28.1%/yr)NAUT compounded faster over this window
Log scale — wide-divergence pair
LYEL NAUT
LYEL vs NAUT: by the numbers
- •NAUT is the larger company ($250M vs $214M market cap).
- •Both run net losses; NAUT's is the smaller (-29747.89% vs -920285.19% net margin).
Metrics side by side
Valuation
| Metric | LYEL | NAUT |
|---|---|---|
| P/S ratio | 7932.15 | 1316.09 |
| P/B ratio | 0.92 | 1.91 |
Profitability
| Metric | LYEL | NAUT |
|---|---|---|
| Gross margin | -31952.78% | 0.00% |
| Operating margin | -566038.89% | 0.00% |
| Net margin | -920285.19% | -29747.89% |
| ROE | -106.27% | -43.11% |
| ROIC | -70.80% | -40.52% |
Growth (annualized)
| Metric | LYEL | NAUT |
|---|---|---|
| Revenue CAGR (5Y) | -68.32% | N/A |
| Total return CAGR (5Y) | -48.18% | -20.56% |
Frequently asked
- How have LYEL and NAUT total returns compared?
- Over the past 5 years, LYEL delivered -48.18% and NAUT delivered -20.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.